<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mario Fontán-Vela</style></author><author><style face="normal" font="default" size="100%">Kissling, Esther</style></author><author><style face="normal" font="default" size="100%">Nathalie Nicolay</style></author><author><style face="normal" font="default" size="100%">Toon Braeye</style></author><author><style face="normal" font="default" size="100%">Izaak Van Evercooren</style></author><author><style face="normal" font="default" size="100%">Christian Holm Hansen</style></author><author><style face="normal" font="default" size="100%">Hanne-Dorthe Emborg</style></author><author><style face="normal" font="default" size="100%">Massimo Fabiani</style></author><author><style face="normal" font="default" size="100%">Alberto Mateo-Urdiales</style></author><author><style face="normal" font="default" size="100%">Ala'a AlKerwi</style></author><author><style face="normal" font="default" size="100%">Susanne Schmitz</style></author><author><style face="normal" font="default" size="100%">Jesús Castilla</style></author><author><style face="normal" font="default" size="100%">Iván Martínez-Baz</style></author><author><style face="normal" font="default" size="100%">Brechje de Gier</style></author><author><style face="normal" font="default" size="100%">Susan Hahné</style></author><author><style face="normal" font="default" size="100%">Hinta Meijerink</style></author><author><style face="normal" font="default" size="100%">Jostein Starrfelt</style></author><author><style face="normal" font="default" size="100%">Baltazar Nunes</style></author><author><style face="normal" font="default" size="100%">Caetano, Constantino</style></author><author><style face="normal" font="default" size="100%">Tarik Derrough</style></author><author><style face="normal" font="default" size="100%">Anthony Nardone</style></author><author><style face="normal" font="default" size="100%">Susana Monge</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">VEBIS-Lot4 working group</style></author><author><style face="normal" font="default" size="100%">VEBIS-Lot 4 working group</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.</style></title><secondary-title><style face="normal" font="default" size="100%">Euro Surveill</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Europe</style></keyword><keyword><style  face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccine Efficacy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Jan</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">29</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65-79-year-olds.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>